Edward Stelmakh
CIK: 0001887046
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
OptimizeRx Corp
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Aug 21, 2026OPRX
OptimizeRx Corp
Tax Payment(F)Direct1.4K shares at avg. $7.71$11K - Dec 23, 2025OPRX
OptimizeRx Corp
Tax Payment(F)Direct3.7K shares at avg. $12.74$47K - Dec 19, 2025OPRX
OptimizeRx Corp
Exercise(M)Direct5.2K shares- - Dec 19, 2025OPRX
OptimizeRx Corp
Tax Payment(F)Direct1.4K shares at avg. $13.51$19K - Dec 19, 2025OPRX
OptimizeRx Corp
Sale(S)Direct1.4K shares at avg. $13.51$19K - Oct 3, 2025OPRX
OptimizeRx Corp
Exercise(M)Direct16.6K shares- - Oct 3, 2025OPRX
OptimizeRx Corp
Tax Payment(F)Direct4.4K shares at avg. $18.75$83K - Aug 21, 2025OPRX
OptimizeRx Corp
Award(A)Direct15.6K shares- - Feb 15, 2025OPRX
OptimizeRx Corp
Tax Payment(F)Direct2.2K shares at avg. $6.64$14K - Dec 23, 2024OPRX
OptimizeRx Corp
Award(A)Direct41.4K shares- - Dec 19, 2024OPRX
OptimizeRx Corp
Tax Payment(F)Direct1.3K shares at avg. $4.75$6K - Dec 19, 2024OPRX
OptimizeRx Corp
Exercise(M)Direct5.2K shares- - Oct 11, 2024OPRX
OptimizeRx Corp
Tax Payment(F)Direct2.1K shares at avg. $6.63$14K - Oct 11, 2024OPRX
OptimizeRx Corp
Exercise(M)Direct8.2K shares- - Oct 3, 2024OPRX
OptimizeRx Corp
Tax Payment(F)Direct4.2K shares at avg. $7.83$33K - Oct 3, 2024OPRX
OptimizeRx Corp
Exercise(M)Direct16.6K shares- - Feb 15, 2024OPRX
OptimizeRx Corp
Award(A)Direct0 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 21, 2026 | OPRX OptimizeRx Corp | Tax Payment(F) | 1,381 | $7.71 | $10,648 | Direct |
| Dec 23, 2025 | OPRX OptimizeRx Corp | Tax Payment(F) | 3,658 | $12.74 | $46,603 | Direct |
| Dec 19, 2025 | OPRX OptimizeRx Corp | Exercise(M) | 5,237 | - | - | Direct |
| Dec 19, 2025 | OPRX OptimizeRx Corp | Tax Payment(F) | 1,388 | $13.51 | $18,752 | Direct |
| Dec 19, 2025 | OPRX OptimizeRx Corp | Sale(S) | 1,388 | $13.51 | $18,752 | Direct |
| Oct 3, 2025 | OPRX OptimizeRx Corp | Exercise(M) | 16,623 | - | - | Direct |
| Oct 3, 2025 | OPRX OptimizeRx Corp | Tax Payment(F) | 4,406 | $18.75 | $82,613 | Direct |
| Aug 21, 2025 | OPRX OptimizeRx Corp | Award(A) | 15,625 | - | - | Direct |
| Feb 15, 2025 | OPRX OptimizeRx Corp | Tax Payment(F) | 2,156 | $6.64 | $14,316 | Direct |
| Dec 23, 2024 | OPRX OptimizeRx Corp | Award(A) | 41,408 | - | $0 | Direct |
| Dec 19, 2024 | OPRX OptimizeRx Corp | Tax Payment(F) | 1,316 | $4.75 | $6,251 | Direct |
| Dec 19, 2024 | OPRX OptimizeRx Corp | Exercise(M) | 5,237 | - | $0 | Direct |
| Oct 11, 2024 | OPRX OptimizeRx Corp | Tax Payment(F) | 2,066 | $6.63 | $13,698 | Direct |
| Oct 11, 2024 | OPRX OptimizeRx Corp | Exercise(M) | 8,222 | - | $0 | Direct |
| Oct 3, 2024 | OPRX OptimizeRx Corp | Tax Payment(F) | 4,177 | $7.83 | $32,706 | Direct |
| Oct 3, 2024 | OPRX OptimizeRx Corp | Exercise(M) | 16,622 | - | $0 | Direct |
| Feb 15, 2024 | OPRX OptimizeRx Corp | Award(A) | 0 | - | $0 | Direct |
1-17 of 17 transactions
About Stelmakh Edward
Stelmakh Edward (SEC CIK 0001887046) files insider reports with the SEC as Chief Finance & Strat Officer of OptimizeRx Corp (OPRX).
Signal8 holds 12 ownership filings by Stelmakh Edward, all Form 4s, filed between Oct 7, 2024 and Aug 24, 2026. Those filings report 17 transactions, from Feb 15, 2024 to Aug 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stelmakh Edward's filings is in WALTHAM, MA.
Recent filings by Stelmakh Edward
- Aug 21, 2026: Tax withholding of OPRX shares (Form 4, code F).
- Dec 23, 2025: Tax withholding of OPRX shares (Form 4, code F).
- Dec 19, 2025: Option exercise of OPRX shares (Form 4, code M).
- Dec 19, 2025: Tax withholding of OPRX shares (Form 4, code F).
- Dec 19, 2025: Open-market sale of OPRX shares (Form 4, code S).
Other insiders filing for OptimizeRx Corp (OPRX)
- D'Silva Andrew J., Chief Business Officer
- Silvestro Stephen L, Chief Executive Officer
- Merrell Brendan W., CHIEF OPERATING OFFICER
- Odence-Ford Marion, Chief Legal & Admin Officer
- KLEMA CATHY, Director
- Lang James Paul, Director